Octreotide LAR as Maintenance Treatment for Patients With NEC

Summary

This is phase II study on the efficacy of octreotide lar as maintenance treatment after first-line chemotherapy for patients with unresectable or metastatic gastro-entero-pancreatic or esophageal neuroendocrine carcinomas.

Timeline

Start

2015-04

Primary completion

2018-11

Completion

2019-06

Drugs

Indications